QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-travere-therapeutics-raises-price-target-to-23

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target fr...

 guggenheim-upgrades-travere-therapeutics-to-buy-announces-25-price-target

Guggenheim analyst Vamil Divan upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and announces $25 price target.

 citigroup-maintains-buy-on-travere-therapeutics-raises-price-target-to-23

Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $...

 b-of-a-securities-maintains-buy-on-travere-therapeutics-raises-price-target-to-19

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-23

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 travere-says-fda-has-granted-full-approval-to-filspari-sparsentan-to-slow-kidney-function-decline-in-adults-with-primary-igan-who-are-at-risk-of-disease-progression

FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based...

 jp-morgan-maintains-overweight-on-travere-therapeutics-raises-price-target-to-20

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

 hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-20

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

 barclays-maintains-overweight-on-travere-therapeutics-raises-price-target-to-14

Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

 piper-sandler-maintains-neutral-on-travere-therapeutics-raises-price-target-to-12

Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...

 wedbush-maintains-outperform-on-travere-therapeutics-raises-price-target-to-16

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from ...

 travere-therapeutics-q2-2024-adj-eps-065-beats-086-estimate-sales-52176m-beat-50169m-estimate

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION